1-3 of 3
Roger G. Ulrich, PhD
Close
Sort by
Journal Articles

CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

Raquel Izumi, PhD, Paul G. Pearson, PhD, Ahmed Hamdy, MD, Sara Rodriquez, MHA, Yolanda Y.L. Yang, MD PhD, Roger G. Ulrich, PhD, Terry Podoll, PhD, Marilee Andrew, PhD, Cecile M. Krejsa, PhD, Tim Ingallinera, BSc, J. Greg Slatter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4996.
https://doi.org/10.1182/blood.V130.Suppl_1.4996.4996
Published: 2017
Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Arnau Montraveta, BS, Carsten U Niemann, MD PhD, Helena Mora-Jensen, PhD, Michael Gulrajani, BS, Fanny Krantz, Bonnie K. Harrington, DVM, Todd Covey, Brian J Lannutti, PhD, Raquel Izumi, PhD, Roger G Ulrich, PhD, John C. Byrd, MD, Adrian Wiestner, MD PhD, Amy J. Johnson, PhD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2015) 126 (23): 2920.
https://doi.org/10.1182/blood.V126.23.2920.2920
Published: 2015
Journal Articles

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

Sarah E. May, Adam Kashishian, Thomas S. Lin, MD, PhD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH, Roger G. Ulrich, PhD, Hao Chen, PhD, Albert S. Yu, MD, PhD, Kamal D. Puri, PhD, BSc, MSc, Brian J. Lannutti, PhD, Neill A. Giese, PhD, John C. Byrd, MD, Amy J. Johnson, PhD
Journal: Blood
Blood (2008) 112 (11): 3165.
https://doi.org/10.1182/blood.V112.11.3165.3165
Published: 2008